每周西妥昔单抗联合紫杉醇治疗复发性或转移性头颈部鳞状细胞癌。
Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
机构信息
Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan
出版信息
In Vivo. 2020 Sep-Oct;34(5):2653-2657. doi: 10.21873/invivo.12084.
BACKGROUND/AIM: Head and neck cancers account for 8% of all cancer cases worldwide. However, identifying the optimal treatment for recurrent or metastatic head and neck cancer (R/MHNSCC) has been challenging. The aim of this study was to evaluate the efficacy, safety, and prognostic factors of the outcome of patients with R/MHNSCC who were treated with weekly cetuximab and paclitaxel (Cmab-PTX).
PATIENTS AND METHODS
The records of R/MHNSCC patients who were treated with Cmab-PTX in our institution between June 2013 and September 2017 were collected. We analyzed Overall survival (OS), progression-free survival (PFS), prognostic factors and adverse events.
RESULTS
The records of 59 patients treated with Cmab-PTX were analyzed. The median PFS was 5.7 months, and the median OS was 11.8 months. Patients who had been administered cetuximab previously had shorter PFS and OS than those who had not.
CONCLUSION
Cmab-PTX may be considered as a treatment option in head and neck R/MHNSCC patients.
背景/目的：头颈部癌症占全球所有癌症病例的 8%。然而，确定复发性或转移性头颈部癌症（R/MHNSCC）的最佳治疗方案一直具有挑战性。本研究旨在评估每周使用西妥昔单抗和紫杉醇（Cmab-PTX）治疗 R/MHNSCC 患者的疗效、安全性和预后因素。
患者和方法
我们收集了 2013 年 6 月至 2017 年 9 月期间在我院接受 Cmab-PTX 治疗的 R/MHNSCC 患者的记录。我们分析了总生存期（OS）、无进展生存期（PFS）、预后因素和不良事件。
结果
分析了 59 例接受 Cmab-PTX 治疗的患者的记录。中位 PFS 为 5.7 个月，中位 OS 为 11.8 个月。先前接受过西妥昔单抗治疗的患者的 PFS 和 OS 短于未接受过治疗的患者。
结论
Cmab-PTX 可被视为 R/MHNSCC 患者的一种治疗选择。
Zotero 插件